EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes

Sae Im Jeong iD, Mu Seong Ban iD, Jun-Gi Hwang iD, Min-Kyu Park iD, Soo Lim iD, Sejoong Kim iD, Soon Kil Kwon iD, Yoonjin Kim iD, Jae Min Cho iD, Jae Jin Na iD, Wan Huh iD, Jae-Yong Chung iD

Diabetes, Obesity and Metabolism · 2024-07 · 26 (7) · 2588-2597

DOI: 10.1111/dom.15573 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 15.04.2024. Verfasst von Sae Im Jeong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju-si, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To explore the effect of renal function on the pharmacokinetic (PK) and pharmacodynamic (PD) profile and safety of enavogliflozin, a selective sodium‐glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes mellitus (T2DM).

Methods

An open‐label, two‐part clinical trial was conducted in T2DM patients, stratified by renal function: Group 1, normal renal function; Group 2, mild renal impairment (RI); Group 3, moderate RI; and Group 4, severe RI. In Part A, Groups 2 and 4 received enavogliflozin 0.5 mg once. In Part B, Groups 1 and 3 received enavogliflozin 0.5 mg once daily for 7 days. Serial blood and timed urine samples were collected to analyse the PK and PD characteristics of enavogliflozin. Pearson's correlation coefficients were calculated to assess the correlations between PK or PD parameters and creatinine clearance (CrCL).

Results

A total of 21 patients completed the study as planned. The area under the curve (AUC) for enavogliflozin was not significantly correlated with CrCL, although the maximum concentration slightly decreased as renal function decreased. By contrast, daily urinary glucose excretion (UGE) was positively correlated with CrCL after both single‐ ( r = 0.7866, p < 0.0001) and multiple‐dose administration ( r = 0.6606, p = 0.0438).

Conclusions

Systemic exposure to oral enavogliflozin 0.5 mg was similar among the patients with T2DM regardless of their renal function levels. However, the glucosuric effect of enavogliflozin decreased with RI. Considering the UGE observed and approved therapeutic use of other SGLT2 inhibitors, the efficacy of enavogliflozin with regard to glycaemic control could be explored in patients with mild and moderate RI (estimated glomerular filtration rate ≥30 or ≥45 mL/min/1.73 m 2 ) in a subsequent larger study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansMaleMiddle AgedFemaleAgedGlomerular Filtration RateBlood GlucoseHypoglycemic AgentsGlucosidesKidneyAdultDiabetic NephropathiesGlycated HemoglobinRenal InsufficiencySodium-Glucose Transporter 2GlycosuriaBenzofurans

Stichwörter der Autor:innen

SGLT2 inhibitorpharmacodynamicspharmacokineticstype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBlood GlucoseHypoglycemic AgentsGlucosidesGlycated HemoglobinSodium-Glucose Transporter 2EnavogliflozinBenzofurans

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Chungbuk National University College of Medicine and Hospital, Cheongju-si, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Internal Medicine, Chungbuk National University College of Medicine and Hospital, Cheongju-si, Republic of Korea.
  • Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.

ORCID-Profile: Sae Im Jeong, Mu Seong Ban, Jun-Gi Hwang, Min-Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae-Yong Chung

Zitieren

APA

Jeong, S. I., Ban, M. S., Hwang, J. G., Park, M. K., Lim, S., Kim, S., Kwon, S. K., Kim, Y., Cho, J. M., Na, J. J., Huh, W., & Chung, J. Y. (2024). The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes. Diabetes, Obesity and Metabolism, 26(7), 2588-2597. https://doi.org/10.1111/dom.15573

Vancouver

Jeong SI, Ban MS, Hwang JG, Park MK, Lim S, Kim S, et al. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes. Diabetes, Obesity and Metabolism. 2024;26(7):2588-2597. doi:10.1111/dom.15573

BibTeX
@article{Jeong2024,
  author = {Jeong, Sae Im and Ban, Mu Seong and Hwang, Jun-Gi and Park, Min-Kyu and Lim, Soo and Kim, Sejoong and Kwon, Soon Kil and Kim, Yoonjin and Cho, Jae Min and Na, Jae Jin and Huh, Wan and Chung, Jae-Yong},
  title = {The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter ‐2 inhibitor, in type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {7},
  pages = {2588--2597},
  doi = {10.1111/dom.15573}
}
Kostenlos starten →